Option chain shows key data for Nanobiotix's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nanobiotix.

Nanobiotix (NASDAQ:NBTX) Stock, Option Chain

Nanobiotix

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Medical,Hospital:,Neurologist,And,Neurosurgeon,Talk,,Use,Computer,,Analyse,Patient

Biotech

Large Cap

News

Health Care

Contracts

General

NBTX

Nanobiotix amended its $2.7 billion licensing deal with Johnson &amp; Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.

Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson &amp; Johnson Agreement To Strengthen Finances And Relieve Funding Burden

C3.ai signage

Pre-Market Outlook

Markets

Movers

Trading Ideas

ASST

CMRX

CPIX

GELS

HUIZ

JTAI

LPTH

MNTS

NEHC

PCSA

RADX

RIME

TNMG

VEEE

VRAR

YEXT

Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

movers image

Intraday Update

AKTS

AULT

BDRX

BNED

BZFD

CSIQ

CTNT

CVAC

DMTK

EDBL

FFIE

FREY

GOGL

IGMS

LFST

LMFA

LULU

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MBIO

MGOL

Eaton Vance Massachusetts Municipal Income Trust

MRNA

NVAX

OBLG

OGEN

PLAB

SPWR

SYTA

VERO

VSAT

VSME

WOOF

Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Nanobiotix SA

Press Releases

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Earnings

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

PARIS:NANO

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Cardiff Oncology

Editas Medicine

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

INmune Bio

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Korro Bio

Lexeo Therapeutics

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Puma Biotechnology

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Tevogen Bio Holdings

Guggenheim

Leerink Partners

Comments

Nanobiotix

Nanobiotix (NBTX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell